Targeting angiogenesis in advanced gastric cancer: Is this end of the road?
作者： Vikram K Jain , David Cunningham
DOI:
关键词:
摘要: Despite recent advances in the management of several solid tumour types, gastric cancer remains a challenging disease to treat. In 2008, accounted for almost one million new cases and over 738,000 deaths, making it fourth most common malignancy second most common cause cancerrelated death world (1).
amegroups.com参考文章(16)
Jacques Ferlay, Hai-Rim Shin, Freddie Bray, David Forman, Colin Mathers, Donald Maxwell Parkin, Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer. ,vol. 127, pp. 2893- 2917 ,(2010) , 10.1002/IJC.25516
Napoleone Ferrara, None, Role of vascular endothelial growth factor in the regulation of angiogenesis Kidney International. ,vol. 56, pp. 794- 814 ,(1999) , 10.1046/J.1523-1755.1999.00610.X
Napoleone Ferrara, Hans-Peter Gerber, Jennifer LeCouter, None, The biology of VEGF and its receptors. Nature Medicine. ,vol. 9, pp. 669- 676 ,(2003) , 10.1038/NM0603-669
Eva Lieto, Francesca Ferraraccio, Michele Orditura, Paolo Castellano, Anna La Mura, Margherita Pinto, Anna Zamboli, Ferdinando De Vita, Gennaro Galizia, Expression of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) is an Independent Prognostic Indicator of Worse Outcome in Gastric Cancer Patients Annals of Surgical Oncology. ,vol. 15, pp. 69- 79 ,(2008) , 10.1245/S10434-007-9596-0
Seong-Eun Kim, Ki-Nam Shim, Sung-Ae Jung, Kwon Yoo, Joo Ho Lee, The Clinicopathological Significance of Tissue Levels of Hypoxia-Inducible Factor-1α and Vascular Endothelial Growth Factor in Gastric Cancer Gut and Liver. ,vol. 3, pp. 88- 94 ,(2009) , 10.5009/GNL.2009.3.2.88
M Inoue, Epidemiology of gastric cancer in Japan Postgraduate Medical Journal. ,vol. 81, pp. 419- 424 ,(2005) , 10.1136/PGMJ.2004.029330
Yung-Jue Bang, Eric Van Cutsem, Andrea Feyereislova, Hyun C Chung, Lin Shen, Akira Sawaki, Florian Lordick, Atsushi Ohtsu, Yasushi Omuro, Taroh Satoh, Giuseppe Aprile, Evgeny Kulikov, Julie Hill, Michaela Lehle, Josef Rüschoff, Yoon-Koo Kang, None, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial The Lancet. ,vol. 376, pp. 687- 697 ,(2010) , 10.1016/S0140-6736(10)61121-X
Molin Wang, Julie Gralow, Maura Dickler, Melody Cobleigh, Edith A. Perez, Tamara Shenkier, David Cella, Nancy E. Davidson, Kathy Miller, Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer The New England Journal of Medicine. ,vol. 357, pp. 2666- 2676 ,(2007) , 10.1056/NEJMOA072113
David Cunningham, Naureen Starling, Sheela Rao, Timothy Iveson, Marianne Nicolson, Fareeda Coxon, Gary Middleton, Francis Daniel, Jacqueline Oates, Andrew Richard Norman, Capecitabine and oxaliplatin for advanced esophagogastric cancer. The New England Journal of Medicine. ,vol. 358, pp. 36- 46 ,(2008) , 10.1056/NEJMC0911925
Ka-Fai To, James Chih-Hsin Yang, Tony S.K. Mok, Masahiro Fukuoka, Yi-Long Wu, Sumitra Thongprasert, Patrapim Sunpaweravong, Swan-Swan Leong, Virote Sriuranpong, Tsu-Yi Chao, Kazuhiko Nakagawa, Da-Tong Chu, Nagahiro Saijo, Emma L. Duffield, Yuri Rukazenkov, Georgina Speake, Haiyi Jiang, Alison A. Armour, Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS) Journal of Clinical Oncology. ,vol. 29, pp. 2866- 2874 ,(2011) , 10.1200/JCO.2010.33.4235